No Data
InnoCare Pharma Limited's (HKG:9969) 6.0% Loss Last Week Hit Both Individual Investors Who Own 37% as Well as Institutions
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Hong Kong stock abnormal movement | Innocare (09969) rose more than 5%, stock-based incentive highlights the company's development confidence. The expansion of immunotherapy and solid tumor pipeline is progressing smoothly.
Innocare (09969) rose over 5%, as of the time of publication, it increased by 5.25%, reaching 7.02 Hong Kong dollars, with a transaction volume of 29.6332 million Hong Kong dollars.
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Hong Kong stocks movement | innocare (09969) rose over 8%, plans to launch a share incentive plan, ICP-332 has currently entered phase III clinical trials.
Innocare (09969) surged more than 8%, as of press time, up 8.12%, trading at 6.68 Hong Kong dollars, with a turnover of 14.4539 million Hong Kong dollars.
